---
title: Immune effector cell-associated enterocolitis following chimeric antigen receptor
  T-cell therapy in multiple myeloma
date: '2024-10-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39414769/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20241017182600&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'We report 14 cases of immune effector cell (IEC)-associated enterocolitis
  following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma,
  with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and 2.2% for ciltacabtagene
  autoleucel). Patients developed acute-onset symptoms (typically non-bloody Grade
  3+ diarrhea) with negative infectious workup beginning a median of 92.5 days (range:
  22-210 days) after CAR-T therapy and a median of 85 days after cytokine release
  ...'
disable_comments: true
---
We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and 2.2% for ciltacabtagene autoleucel). Patients developed acute-onset symptoms (typically non-bloody Grade 3+ diarrhea) with negative infectious workup beginning a median of 92.5 days (range: 22-210 days) after CAR-T therapy and a median of 85 days after cytokine release ...